This site is intended for healthcare professionals
News

Complete Response for vadadustat to treat anemia due to chronic kidney disease.- Akebia Therapeutics

Read time: 1 mins
Published:31st Mar 2022

Akebia Therapeutics, Inc. announced that the FDA has issued a complete response letter (CRL) to Akebia's New Drug Application (NDA) for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor under review for the treatment of anemia due to chronic kidney disease (CKD).

The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.

The FDA concluded that the data in the NDA do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients. The FDA expressed safety concerns noting failure to meet non-inferiority in MACE in the non-dialysis patient population, the increased risk of thromboembolic events, driven by vascular access thrombosis in dialysis patients, and the risk of drug-induced liver injury. The CRL stated that Akebia could explore ways to potentially demonstrate a favorable benefit-risk assessment through new clinical trials. Akebia will discuss the details of the CRL with its collaboration partners and request a meeting with the FDA.

Condition: Anaemia and CKD
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.